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SESSION II
METHODOLOGY ISSUES—Clinical Outcomes
Study Issues
PMD1
THE NEW METHOD FOR TIME ADJUSTMENT
OF THE NUMBER NEEDED TO TREAT AND ITS
APPLICATION TO PHARMACOECONOMICS
ANALYSIS
Aino H,Yanagisawa S, Kamae I
Kobe University, Kobe, Japan
The number needed to treat (NNT) is a benchmark
invented in evidence-based medicine to describe the incre-
mental effect between two medical treatments. Although
it is potentially useful on pharmacoeconomics, the 
estimate is limited to be valid at a certain endpoint of a
clinical trial. OBJECTIVE: To overcome such time-
constraint, we developed a new method that can stan-
dardize the NNT to ex/intrapolate over the time axis.
METHOD: We reviewed a linear approximation model
in which the absolute risk reduction (ARR), the recipro-
cal of the NNT, is directly proportional to the duration
of the clinical trial. Then, we extended the linear model
into a more complex model using exponential function to
ex/interpolate the NNT, and also developed mathemati-
cally how to calculate the incremental cost-effectiveness
ratio according to the standardized NNT. RESULTS: We
found the linear model has a fatal disadvantage that the
time-adjusted ARR can be larger than 1 (i.e., the time-
adjusted NNT can become impractically smaller than 1)
under the assumption of constant relative risk reduction
and constant event rate over time. On the other hand, the
exponential model was able to overcome such a disad-
vantage in consistency with practical assumptions. CON-
CLUSION: The exponential model is practically better
than linear model to standardize the NNT. The method
we developed is applicable to estimate the incremental
cost-effectiveness introducing the ratio of incremental
cost per person responded to a treatment.
PMD2
THE USE OF DISCRETE CHOICE MODELLING
IN THE DESIGN OF CLINICAL TRIALS
Backhouse ME
Research Triangle Institute, Manchester, United Kingdom
OBJECTIVE: Discrete choice modelling (DCM) applied
to data generated by stated preference (SP) experiments
is being used increasingly by health economists as a
method for valuing process and outcome characteristics
of health interventions in utility or monetary terms. The
purpose of this paper is to illustrate how sponsors of ran-
domised controlled trials (RCTs) could use DCM to assist
with the planning of their studies. The approach is 
illustrated using a case study of the design of trials to 
evaluate the use of adjuvant bisphosphonates in the 
management of patients with primary operable breast
cancer. METHODS: A stated preference experiment was
conducted amongst UK specialists involved in the 
management of patients with primary operable breast
cancer. Respondents were asked to choose 1 bisphospho-
nate regimen from each of 16 binary choice scenarios.
Each regimen was characterised in terms of the following
trial design attributes: 1) Primary endpoint; 2) Effect size
demonstrated; 3) Uncertainty surrounding demonstrated
effect; 4) Duration of observation; 5) Study population;
and 6) Cost of the treatment alternatives. The survey was 
performed using a telephone-mail-telephone approach.
Probit analysis was used to estimate a binary choice
model of drug prescribing behaviour. RESULTS: 54 
specialists fully completed the survey questionnaire 
providing a sample of 864 discrete choice responses. In
qualitative terms, the signs on the coefﬁcients were in line
with prior expectations and all coefﬁcients were statisti-
cally signiﬁcant at conventional levels. The marginal and
average effects were used to determine the relative impor-
tance of the attributes and to rank alternative designs in
terms of the ex ante probabilities of product adoption.
CONCLUSIONS: DCM could be used by sponsors of
RCTs to incorporate decision-maker preferences into
their designs. It could also be used to estimate product
uptake contingent upon different designs. Results from
this study suggest that the approach is both feasible and
valid.
PMD3
RELEVANCE OF PATIENT REPORTED
OUTCOMES FOR CHRONIC PAIN PATIENTS:
THE ROLE OF SATISFACTION WITH
ANALGESIC MEDICATION AND APPLICATION
FORM
Anderson-Hillemacher A1, Hastedt C1, Pösl M2
1Gruenenthal GmbH, Aachen, Germany; 2Institute for Medical
Psychology, University of Munich, München, Germany
OBJECTIVES: Patient satisfaction is a multi-facet 
construct and an important parameter of patient 
reported outcomes (PRO). In order to be able to measure
chronic pain patient’s satisfaction, the relevance of dif-
ferent dimensions were identiﬁed, with a focus on the role
of analgesic medication. METHOD: First, a literature
review was conducted to summarise the current instru-
ments of PRO measures. To identify relevant dimensions
of patient’s satisfaction, 4 focus groups were held (10
patients with tumour pain, 10 with non-tumour pain). 
In semi-standardised interviews, patients’ personal pain
experience and articulation were explored, including their
satisfaction with analgesics in different dosage forms
(oral, transdermal). RESULTS: Besides HRQoL and other
parameters, the PRO referred to the literature also include
a reference to the importance of data relating to patient
satisfaction. To date, instruments used to survey patient
satisfaction have three dimensions: 1) Satisfaction with
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clinical care (doctor-patient relationship, competence 
of nursing staff, etc.); 2) Satisfaction with physical 
surroundings (medical facilities, organisational structure,
etc.); 3) Satisfaction with clinical outcomes (result of
treatment, impairment due to side effects, etc.) In the
focus groups patients reported that analgesics and their
application forms have an impact on acceptance, com-
pliance, and on several areas of life such as sleep and life
style. CONCLUSIONS: The results of the focus groups
support the assumption, that at least one further dimen-
sion of patient’s satisfaction exists: satisfaction with
medical treatment. This aspect has not yet been taken up
by theoretical or empirical research. Due to this, world
wide there is no instrument for recording this dimension
today. The need to develop a new questionnaire to estab-
lish patients level of acceptance and satisfaction with 
their medication was speciﬁed and suggestions for a 4-
dimensional model of patient’s satisfaction were made.
PMD4
WHEN CAN MISSING DATA BE CONSIDERED
MISSING AT RANDOM (MAR) IN SUBSTANCE
ABUSE TREATMENT OUTCOMES RESEARCH?
Ciesla JR, Spear SF
Northern Illinois University, DeKalb, IL, USA
OBJECTIVES: A lot of attention is focused on the
outcome effectiveness of substance abuse treatment. The
usual method of assessing outcomes is by contacting
clients after treatment and querying them on recovery-
related behaviors and on drug/alcohol use. Since
researchers are not always able to contact every client
after treatment, the issue of response bias is important.
Missing data is MAR, and thus ignorable, if differences
between respondents and nonrespondents can be charac-
terized by variables that are measured for both groups.
The objective of this research is to illuminate this issue by
using data collected from a U.S. treatment population and
to discuss statistical methods for correcting response bias.
METHODS: The data were collected from treatment
records and follow-up interviews of clients completing
substance abuse treatment at a facility in the U.S. Appro-
priate consent was obtained. Each client contacted was
administered a questionnaire. Eighty-eight (44.9%) com-
pleted the questionnaire; 102 (52.4%) could not be con-
tacted. Since the treatment records for the responders and
nonresponders were available, information was extracted
on variables related to treatment outcomes so that statis-
tical analysis could be conducted. RESULTS: No differ-
ences were found between responders and nonresponders
for most variables. Variables measuring demographics,
family support/structure, criminality/truancy, psychologi-
cal comorbidities, treatment attributes, and drug use were
not different. Variables with statistically signiﬁcant dif-
ferences were: “number of months at current residence”
(t = 2.12 p = .037) and the proportion “holding jobs”
(difference in proportions = .182; 95% CI = .043 to .321).
CONCLUSIONS: Missing data are not MAR, and thus
not ignorable, when missing variables are the same as or
related to variables that determine outcomes. In this case
“number of months at current residence” and “holding a
job” may predict treatment success. If this is true, some
method of control must be used. Weighting adjustments
such as post-stratiﬁcation and likelihood-based methods
are considered. Since the variables that predict treatment
outcomes are not fully understood, it is difﬁcult to be
certain MAR criteria are met.
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PMD5
VALUATION OF NEW DRUG APPLICATIONS OF
PHARMACEUTICAL COMPANIES USING
COMPOUND OPTION MODELS
Cassimon D, Engelen PJ, Thomassen L,Van Wouwe M
University of Antwerp, Antwerpen, Belgium
OBJECTIVES: This paper presents a model based on real
option analysis for the valuation of R&D in the phar-
maceutical sector both for start-up ventures as well as big
conglomerates. We derive a formal compound option
model to value New Drug Applications (NDA) and show
the valuable contribution of real option analysis com-
pared to conventional DCF-analysis. METHODS: The
key understanding is that R&D projects of NDAs can be
seen as compound options. The growth option frame-
work looks at pharmaceutical investment projects as a
sequence of options, which differs from a conventional
DCF-analysis by incorporating the possibility to stop 
the project when a subsequent phase is not valuable
(abandon the option), and only continues with the project
(exercising the option) when it is valuable. Traditional
valuation techniques as DCF-analysis fail in valuing 
innovative companies because most of the value of R&D
projects is embedded in unexercised real options whose
future value is uncertain at this moment. If one considers
a company as a portfolio of real options, one can value
the projects or the company based on a compound option
model. RESULTS: The compound option model reveals
that real option analysis can better incorporate the value
of a NDA than conventional DCF-analysis would reveal.
Real option analysis will better reﬂect the fundamental
value of the project or of the company, which cannot be
captured by DCF-analysis. CONCLUSION: The paper
presents a new methodology for valuing R&D of 
pharmaceutical companies based on compound option
models.
PMD6
MODIFYING COST-EFFECTIVENESS RATIOS TO
BE MAXIMALLY COMPARABLE ACROSS
MULTIPLE DISEASES:AN APPLICATION OF
MANIFOLD THEORY
Gold K, Botteman M, Pashos C
Abt Associates Inc, Cambridge, MA, USA
OBJECTIVE: Develop methodology to create a more
globally informative, CE-based “valuation” that is useful
